NCT06643637View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 8, 2024

Primary Completion Date

March 12, 2025

Study Completion Date

March 12, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

Psilocybin

Capsule containing active ingredient, psilocybin

DRUG

Placebo

Capsule with no active ingredients

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors
All Listed Sponsors
lead

MycoMedica Life Sciences PBC

INDUSTRY